Latest news with #MedicalDevelopmentsInternational
Yahoo
19-05-2025
- Business
- Yahoo
One Medical Developments International Insider Raised Stake By 42% In Previous Year
From what we can see, insiders were net buyers in Medical Developments International Limited's (ASX:MVP ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Over the last year, we can see that the biggest insider purchase was by insider David Williams for AU$3.3m worth of shares, at about AU$2.07 per share. That means that an insider was happy to buy shares at above the current price of AU$0.59. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was David Williams. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for Medical Developments International There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Medical Developments International insiders own 15% of the company, worth about AU$9.7m. We do generally prefer see higher levels of insider ownership. There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Medical Developments International stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 3 warning signs we've spotted with Medical Developments International (including 1 which is potentially serious). If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Globe and Mail
12-03-2025
- Health
- Globe and Mail
Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts
The Key Burn Pain Companies in the market include - Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others. DelveInsight's 'Burn Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Burn Pain, historical and forecasted epidemiology as well as the Burn Pain market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Burn Pain Market Report: The Burn Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In August 2024, MediWound Ltd. (Nasdaq: MDWD), a global leader in enzymatic therapeutics for tissue repair, announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients from newborns to 18 years old with deep partial- and full-thickness thermal burns. This approval expands NexoBrid's authorization for all age groups in the U.S., aligning with its approvals in the European Union and Japan. In 2023, the US maintained the largest market share among the 7MM, reaching USD 140 million. Projections indicate that this trend will persist, with the US expected to further strengthen its market dominance and remain the leading player by 2034. In 2023, Germany and the UK in the EU4 and the UK both achieved market shares exceeding USD 20 million, with France following closely behind. In contrast, Italy had the smallest market share among these regions during the same period. Opioid analgesics dominated the current treatment market for both inpatient and outpatient care, with an estimated market value of approximately USD 130 million in 2023. In 2023, the US recorded over 2 million incident cases of burns, with numbers expected to rise by 2034. In 2023, approximately 0.4 million treated incident burn cases requiring pain management therapies were reported in the US, with expectations for change during the study period from 2020 to 2034. The gender distribution indicates a male dominance across the 7MM, with around 0.29 million male cases and 0.26 million female cases reported in the US in 2023. Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others The Burn Pain epidemiology based on etiology-specific cases analyzed that Etiology Specific Incident Cases of Burns is classified into Flame, Contact, Scald, Electrical, Chemical, and Others The Burn Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Burn Pain pipeline products will significantly revolutionize the Burn Pain market dynamics. Burn Pain Overview An organic tissue injury known as a burn is mostly brought on by heat, radiation, radioactivity, electricity, friction, or chemical contact. Get a Free sample for the Burn Pain Market Report - Burn Pain Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Burn Pain Epidemiology Segmentation: The Burn Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Burn Pain Prevalent Cases of Burn Pain by severity Gender-specific Prevalence of Burn Pain Diagnosed Cases of Episodic and Chronic Burn Pain Download the report to understand which factors are driving Burn Pain epidemiology trends @ Burn Pain Epidemiology Forecast Burn Pain Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Burn Pain market or expected to get launched during the study period. The analysis covers Burn Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Burn Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Burn Pain Therapies and Key Companies Burn Pain Market Strengths The increasing incidence of patients with burns is expected to propel the treatment market in the future, adding opportunities for new pharma players Burn Pain Market Opportunities The rising incidence of burn pain indicates increasing pharmacological treatment demands, thereby crafting lucrative opportunities for new pharma players Scope of the Burn Pain Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Burn Pain Companies: Medical Developments International, Cumberland Pharmaceuticals, Janssen Research & Development, Cephalon, and others Key Burn Pain Therapies: Methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, ACTIQ, and others Burn Pain Therapeutic Assessment: Burn Pain current marketed and Burn Pain emerging therapies Burn Pain Market Dynamics: Burn Pain market drivers and Burn Pain market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Burn Pain Unmet Needs, KOL's views, Analyst's views, Burn Pain Market Access and Reimbursement Table of Contents 1. Burn Pain Market Report Introduction 2. Executive Summary for Burn Pain 3. SWOT analysis of Burn Pain 4. Burn Pain Patient Share (%) Overview at a Glance 5. Burn Pain Market Overview at a Glance 6. Burn Pain Disease Background and Overview 7. Burn Pain Epidemiology and Patient Population 8. Country-Specific Patient Population of Burn Pain 9. Burn Pain Current Treatment and Medical Practices 10. Burn Pain Unmet Needs 11. Burn Pain Emerging Therapies 12. Burn Pain Market Outlook 13. Country-Wise Burn Pain Market Analysis (2020–2034) 14. Burn Pain Market Access and Reimbursement of Therapies 15. Burn Pain Market Drivers 16. Burn Pain Market Barriers 17. Burn Pain Appendix 18. Burn Pain Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
21-02-2025
- Business
- Yahoo
Shareholders in Medical Developments International (ASX:MVP) have lost 90%, as stock drops 13% this past week
This month, we saw the Medical Developments International Limited (ASX:MVP) up an impressive 96%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 90%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. With the stock having lost 13% in the past week, it's worth taking a look at business performance and seeing if there's any red flags. View our latest analysis for Medical Developments International Given that Medical Developments International didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last half decade, Medical Developments International saw its revenue increase by 11% per year. That's a fairly respectable growth rate. So the stock price fall of 14% per year seems pretty steep. The market can be a harsh master when your company is losing money and revenue growth disappoints. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Medical Developments International stock, you should check out this free report showing analyst profit forecasts. While the broader market gained around 12% in the last year, Medical Developments International shareholders lost 10%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 14% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Medical Developments International has 3 warning signs (and 2 which make us uncomfortable) we think you should know about. Medical Developments International is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
21-02-2025
- Business
- Yahoo
Shareholders in Medical Developments International (ASX:MVP) have lost 90%, as stock drops 13% this past week
This month, we saw the Medical Developments International Limited (ASX:MVP) up an impressive 96%. But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. Five years have seen the share price descend precipitously, down a full 90%. It's true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. With the stock having lost 13% in the past week, it's worth taking a look at business performance and seeing if there's any red flags. View our latest analysis for Medical Developments International Given that Medical Developments International didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last half decade, Medical Developments International saw its revenue increase by 11% per year. That's a fairly respectable growth rate. So the stock price fall of 14% per year seems pretty steep. The market can be a harsh master when your company is losing money and revenue growth disappoints. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling Medical Developments International stock, you should check out this free report showing analyst profit forecasts. While the broader market gained around 12% in the last year, Medical Developments International shareholders lost 10%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, longer term shareholders are suffering worse, given the loss of 14% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Medical Developments International has 3 warning signs (and 2 which make us uncomfortable) we think you should know about. Medical Developments International is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
